Celldex Therapeutics, Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-12-08

Reporting Person: Crowley Elizabeth (Sr. VP &CPDO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	M	4000	$9.0165	Acquired	8726	Direct
2021-12-08	Common Stock	S	4000	$40.00	Disposed	4726	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Incentive Stock Option (Right to Buy)	$9.0165	M	4000	Disposed	2028-06-13	Common Stock (4000)	Direct

Footnotes

F1: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F2: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.

F3: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.